Similar articles

• 4-hydroperoxycyclophosphamide: a model for eliminating residual human tumour cells and T-lymphocytes from the bone marrow graft.

  Körbling M, Hess AD, Tutschka PJ, Kaizer H, Colvin MO, Santos GW. Körbling M, et al. Br J Haematol. 1982 Sep;52(1):89-96. doi: 10.1111/j.1365-2141.1982.tb03864.x. Br J Haematol. 1982. PMID: 6214268
• Survival of hematopoietic and lymphoma colony-forming cells in vivo following the administration of a variety of alkylating agents.

  Valeriote FA, Tolen SJ. Valeriote FA, et al. Cancer Res. 1972 Mar;32(3):470-6. Cancer Res. 1972. PMID: 4621955 No abstract available.
• Sparing of suppressor cells: a critical action of cyclosporine.

  Kupiec-Weglinski JW, Filho MA, Strom TB, Tilney NL. Kupiec-Weglinski JW, et al. Transplantation. 1984 Aug;38(2):97-101. doi: 10.1097/00007890-198408000-00001. Transplantation. 1984. PMID: 6235650 No abstract available.
• Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s).

  Siena S, Bregni M, Bonsi L, Strippoli P, Peccatori F, Magni M, Di Nicola M, Bagnara GP, Massimo Gianni A. Siena S, et al. Stem Cells. 1993 Jul;11 Suppl 2:72-5. doi: 10.1002/stem.5530110812. Stem Cells. 1993. PMID: 8104618 Review.
• Mobilization of peripheral stem cells for transplantation.

  Nemunaitis J, Rosenfeld C. Nemunaitis J, et al. J Hematother. 1993 Fall;2(3):351-5. doi: 10.1089/scd.1.1993.2.351. J Hematother. 1993. PMID: 7921995 Review. No abstract available.